Big News Just Out on CEYY!
Fresh Start Private Management, Inc. Announces Second California Clinic Opening
Fresh Start Private Management Inc.
601 N. Parkcenter Drive
Suite 103
Santa Ana, CA 92705
Phone: 714-462-4880
freshstartprivate.com
PROFILE:
Fresh Start Private Management, Inc. (OTCBB: CEYY) is an alcohol treatment and rehabilitation company on the leading edge of alcohol addiction treatment. The company has developed a treatment program that is used by various licensed alcohol addiction clinics throughout the United States.
The program consists of two components:
- Fresh Start Private has the worldwide rights (except in Australia and New Zealand) to a highly effective, proprietary implant formulation of the FDA-approved drug, naltrexone. After being surgically implanted by a medical professional, the naltrexone implant significantly reduces cravings for alcohol for as long as a year in some patients, depending on individual metabolism rates.
- Fresh Start Private also owns a life coaching program that is tailored specifically to alcoholics. Once a patient has received the implant, they are encouraged to enter the life coaching program to maximize results.
Fresh Start Private’s revolutionary alcohol treatment program has an 85% success rate as reported by patients in routine telephone and face to face interviews. The implant is administered as an outpatient procedure, and in most cases, patients do not need to miss more than one day of work. They are then able to enter the private life coaching program without co-workers or family members knowing, unless they so choose.
Value Proposition:
- CEYY just completed its strongest two quarters to date.
- Tight float: CEYY completed a large buyback and retirement in 2012 of 27 million shares and retirement of outstanding common stock
- Excellent management team. Newly appointed CEO, Kent Emry, brings a vast knowledge of operational systems and extensive experience in contract negotiations with reimbursement entities.
- Expansion of the Board of Directors to create a more balanced board.
- Fresh Start Private has the worldwide rights (except in Australia and New Zealand) to a highly effective, proprietary implant formulation of the FDA-approved drug, Naltrexone.
- Fresh Start Private has developed a one on one coaching program tailored specifically to the treatment of alcoholism.
- Clinics using the Fresh Start Private program report an 85% success rate with patients that complete the entire program
- Vast US Market: Some studies report that 10-20 million people in the US have a drinking problem and the cost of alcoholism to society can top 100-200 billion dollars annually.
- Rare combination of tremendous profit potential and dramatic positive social impact for millions of Americans and all those who are affected by the evils of alcohol addiction.
Investors Overview
Fresh Start Private is uniquely poised to gain significant market share of the 22 billion dollar annual alcohol treatment market in the US.
More than 7% of the US population ages 18 years and older or 13.8 million Americans have problems with drinking, including 8.1 million people who suffer from alcoholism. And the costs financially are staggering. Alcohol dependency and abuse costs the US over 220 billion dollars a year. For the sake of comparison, this is greater than the amount of money spent to combat cancer (196 billion dollars) and obesity (133 billion dollars).
Fresh Start Private intends to distribute the program to a new clinic in the United States every 60 to 90 days. Clinics using our program are also holding discussions with major health insurance providers to pay for all or a portion of the treatment fees.
Business Model
Fresh Start Private’s research has discovered that demand for its services are high and that growth in highly marketed segments of the population may be achieved through partnering with additional clinic sites. The company is also exploring the sub-licensing of the program to select regions of the US and internationally.
Fresh Start Private's goal is to meet its growth targets through licensing opportunities by promoting its naltrexone implant product and counseling service model to existing medical clinics and treatment centers that will purchase the program and/or product from the company. In addition, Fresh Start Private intends to open corporately owned clinics in select key markets where it is deemed appropriate. |
|
OTCQB: CEYY
Market Value:
3,536,055 a/o Sep 26, 2013
Shares Outstanding:
117,868,501 a/o Aug 19, 2013
Authorized Shares:
200,000,000 a/o Apr 21, 2011
Par Value:
0.001
Shareholders of Record:
54 a/o Apr 15, 2013
Short Selling Data:
Short Interest 1,798 (-0.55%)
Sep 13, 2013
Transfer Agent:
Columbia Stock Transfer Company
RECENT NEWS:
Major Insurance Carrier Now Reimbursing for Fresh Start Private Program
Fresh Start Private Management, Inc. Appoints Kent Emry New Chief Executive Officer
KEY EXECUTIVES:
Kent Emry
CEO
Director
Dr. Jorge Andrade, Jr.
Chairman
Director
Co-founder
Neil Muller
Co-Founder
President
Director
Lourdes Felix
CFO
Director
Brady Granier
COO
Director
|
